跳至主要内容
临床试验/NCT03702426
NCT03702426已完成不适用

Comparison of the Efficacy of Granulocyte - Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis - A Randomised Controlled Trial

Institute of Liver and Biliary Sciences, India1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2018年7月23日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
120
试验地点
1
主要终点
Spontaneous Bacterial Peritonitis on secondary prophylaxis in both groups

研究概览

简要总结

-Consecutive patients of decompensated cirrhosis of any etiology, presenting to the Institute of Liver and Biliary Sciences hospital with spontaneous bacterial peritonitis will be evaluated

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 - 70years
  • Patients of decompensated liver cirrhosis who present with spontaneous bacterial peritonitis (Presence of more than 250 neutrophils per cc of ascitic fluid, in the absence of a surgical abdomen, in the presence of decompensated cirrhosis and portal hypertension) that has responded to standard medical care.

排除标准

  • Allergic to quinolones
  • Advanced HCC (Hepatocellular Carcinoma)
  • Post liver transplant
  • HIV (Human Immunodeficiency Virus) positive patients
  • Patients on immunosuppressive therapy
  • Pregnancy
  • Acute Liver Failure
  • History of hematological malignancy or bone marrow transplantation
  • No informed consent

研究组 & 干预措施

Norfloxacin with GM-CSF

Experimental

Oral Norfloxacin 400mg daily and GM-CSF (Granulocyte-Macrophage colony-stimulating factor) in a dose of 1.5mcg/kg over 4 hour infusion every 15 days will be given in Group B

干预措施: GMCSF (Drug)

Norfloxacin with GM-CSF

Experimental

Oral Norfloxacin 400mg daily and GM-CSF (Granulocyte-Macrophage colony-stimulating factor) in a dose of 1.5mcg/kg over 4 hour infusion every 15 days will be given in Group B

干预措施: Norfloxacin (Drug)

Norfloxacin

Active Comparator

Patients who fulfil the inclusion criteria will receive oral norfloxacin 400 mg daily as secondary prophylaxis for SBP in Group A.

干预措施: Norfloxacin (Drug)

结局指标

主要结局

Spontaneous Bacterial Peritonitis on secondary prophylaxis in both groups

时间窗: 6 Month

Spontaneous Bacterial Peritonitis is defined as Polymorphonuclear count \> 250 in ascitic fluid

次要结局

  • Survival in both groups after development of SBP (Spontaneous Bacterial Peritonitis ).(48 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验